BioSpace News Archive

Retractable Technologies, Inc. reports the following information relating to the year ended December 31, 2021.

Idera Pharmaceuticals, Inc. reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the year ended December 31, 2021.

SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics, Inc. announced that the companies have entered into an exclusive license agreement that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective small molecule cyclin-dependent kinase 9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.

USWM, LLC, and Adamis Pharmaceuticals Corporation, announced the U.S. launch and availability of ZIMHI™ 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), today announced the publication of a study evaluating the use of a sufentanil sublingual tablet (SST) 30 mcg for management of pain of radiofrequency (“RF”) microneedling of the face or abdomen.

The Gastric Cancer Foundation has announced the launch of its 2022 grant program.

Pulse Biosciences, Inc., a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ technology, announced financial results for the fourth quarter and full year of 2021.